Table 3.

Outcomes in Patients With FPLD With Pathogenic Variants in PPARG and LMNA Genes Before vs After 12 Months of Metreleptin

	PPARG Variant Group			LMNA Variant Group
Clinical Variables	Baseline (n = 7)	12 Months (n = 7)	P Value	Baseline (n = 22)	12 Months (n = 22)	P Value	P Value for Combined Group	P Value for Metreleptin × Genetic Interaction
Weight, kg	64 ± 13	65 ± 14	0.5	70 ± 13	68 ± 13	0.006	0.036	0.06
BMI, kg/m2	24.4 ± 2.2	25.2 ± 2.5	0.3	25.7 ± 3.4	24.9 ± 3.4	0.01	0.2	0.02

Glycemic Parameters
Fasting glucose, mg/dL	177 ± 97	158 ± 81	0.9	180 ± 89	124 ± 49	0.0001	0.005	0.3
Fasting insulin, µU/mLa	70 [27, 144]	76 [27, 105]	1.0	15 [11, 42]	18 [9, 56]	0.6	0.7	0.9
Fasting C-peptide, ng/mLa	3.7 [0.9, 5.2]	3.5 [1.6, 6.1]	0.7	4.1 [3.2, 4.9]	3.4 [2.2, 4.5]	0.02	0.07	0.1
Hemoglobin A1c, %	9.2 ± 2.3	7.7 ± 2.4	0.02	7.8 ± 2.1	7.3 ± 1.7	0.01	0.0005	0.06
Insulin dose, U/kg/da	3.8 [2.7, 4.3]	2.0 [1.6, 3.0]	0.03	1.7 [1.3, 4.]	1.2 [0.9, 2.3]	0.02	0.0002	0.8
Number of diabetic medications	2.6 ± 0.8	2.6 ± 0.8	1.0	1.6 ± 0.9	1.4 ± 1.0	0.1	0.1	0.3

Lipid Parameters
Total cholesterol, mg/dLa	321 [155, 415]	202 [140, 209]	0.08	205 [153, 243]	175 [161, 218]	0.1	0.01	0.01
Triglycerides, mg/dLa	1377 [278, 5577]	680 [296, 783]	0.2	332 [198, 562]	293 [148, 406]	0.001	0.002	0.1
HDL-C, mg/dL	27 ± 5	25 ± 5	1.0	34 ± 10	35 ± 10	0.3	0.3	0.3
LDL-C, mg/dL	60 ± 14	88 ± 58	0.4	98 ± 31	103 ± 35	0.7	0.5	0.9
Number of lipid-lowering medications	1.9 ± 0.7	1.6 ± 0.8	0.6	1.1 ± 0.8	1.1 ± 0.9	0.7	0.7	0.2

Hepatic Parameters
Alanine aminotransferase, U/La	36 [20, 46]	29 [23, 52]	1.0	29 [23, 47]	29 [19, 44]	0.2	0.2	0.8
Aspartate aminotransferase, U/La	25 [18, 37]	26 [17, 40]	0.9	25 [19, 30]	21 [18, 27]	0.2	0.5	0.8

Data are presented as mean and ± SD. P < 0.05 is considered statistically significant.

Abbreviations: AUC, area under the curve; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

^aRepresents data as median [25th percentile, 75th percentile].